Gunderson Dettmer advised Photys Therapeutics on the deal.Photys Therapeutics, a developer of phosphorylation-inducing chimeric small molecule (PHICS) medicines, announced its $75 million Series A financing led…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
